This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through March 4, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
by Zacks Equity Research
Aldeyra (ALDX) rises 43% in one week, driven by plans to initiate a pivotal study to support the resubmission of reproxalap NDA for dry eye disease in the first half of 2024.
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
by Zacks Equity Research
Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.
Here's Why You Should Invest in Aldeyra (ALDX) Stock Now
by Zacks Equity Research
Here, we discuss some reasons why investing in Aldeyra Therapeutics (ALDX) stock now may turn out to be a prudent move.
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.
Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics
by Zacks Equity Research
United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics are part of the Zacks Industry Outlook article.
5 Small Drug Stocks to Buy From a Rebounding Industry
by Kinjel Shah
Innovation is expected to continue to drive growth of the Medical-Drugs industry. UTHR, ESPR, HRTX, LYRA and ALDX may prove to be good additions to one's portfolio.
Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) reports encouraging fourth-quarter results as earnings and sales beat estimates. Management reiterates the 2024 financial outlook.
Oracle (ORCL) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Oracle's (ORCL) fiscal second-quarter 2024 performance is expected to have benefited from continued demand for cloud infrastructure services.
Semtech (SMTC) to Release Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Semtech's (SMTC) third-quarter fiscal 2024 results are expected to reflect solid momentum in the industrial market amid macroeconomic challenges.
Should You Buy Aldeyra Therapeutics (ALDX) Ahead of Earnings?
by Zacks Equity Research
Aldeyra Therapeutics (ALDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BOX Gears Up to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
BOX's fiscal third-quarter results are likely to reflect strength in content cloud solutions.
What's in Store for Patterson Companies (PDCO) in Q2 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal second-quarter results are likely to reflect an improvement in both the Dental and Animal Health segments.
Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More
by Ekta Bagri
Regulatory and pipeline updates from Aldeyra Therapeutics (ALDX) and Scholar Rock (SRRK) are in focus in the biotech sector.
Aldeyra (ALDX) Plummets on Dry Eye Disease Drug's Setback
by Zacks Equity Research
Aldeyra's (ALDX) new drug application for dry eye disease unlikely to be approved by the FDA due to its lack of efficacy.
Can Aldeyra Therapeutics, Inc. (ALDX) Climb 107.66% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Aldeyra Therapeutics, Inc. (ALDX) points to a 107.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Alderya (ALDX) Stock Declines on Getting CRL for PVRL Candidate
by Zacks Equity Research
Alderya's (ALDX) shares decline on receiving a complete response letter for an investigational candidate, ADX-2191, treating primary vitreoretinal lymphoma.
Aldeyra (ALDX) Up On Positive Data From Conjunctivitis Study
by Zacks Equity Research
Aldeyra (ALDX) soars on meeting primary and secondary endpoints in the late-stage study of reproxalap for patients with allergic conjunctivitis.
Aldeyra Therapeutics, Inc. (ALDX) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Aldeyra's (ALDX) Dry Eye Disease Chamber Study Meets Goals
by Zacks Equity Research
Aldeyra's (ALDX) vehicle-controlled crossover study evaluating 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease meets primary endpoints. Shares up.
Palatin (PTN) Begins Phase III Study For Dry Eye Disease
by Zacks Equity Research
Palatin (PTN) commences the pivotal phase III study evaluating PL9643 for the treatment of dry eye disease. Top-line data from the same is expected in the second half of 2022.
Do Options Traders Know Something About Aldeyra (ALDX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Aldeyra (ALDX) stock based on the movements in the options market lately.
Implied Volatility Surging for Aldeyra (ALDX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Aldeyra (ALDX) stock based on the movements in the options market lately.
Aldeyra's (ALDX) ADX-2191 Gets Orphan Drug Tag for Rare Cancer
by Zacks Equity Research
The FDA grants an Orphan Drug designation to Aldeyra's (ALDX) ADX-2191 for the treatment of primary vitreoretinal lymphoma.
Why Earnings Season Could Be Great for Aldeyra Therapeutics (ALDX)
by Radhika Saraogi
Aldeyra Therapeutics (ALDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in Store for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.